Opaleye Management as of March 31, 2024
Portfolio Holdings for Opaleye Management
Opaleye Management holds 52 positions in its portfolio as reported in the March 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Ocular Therapeutix (OCUL) | 13.2 | $61M | 6.7M | 9.10 | |
Harrow Health (HROW) | 11.3 | $52M | 3.9M | 13.23 | |
Tg Therapeutics (TGTX) | 7.6 | $35M | 2.3M | 15.21 | |
Keros Therapeutics (KROS) | 5.3 | $24M | 368k | 66.20 | |
Rhythm Pharmaceuticals (RYTM) | 4.9 | $22M | 515k | 43.33 | |
Catalyst Pharmaceutical Partners (CPRX) | 3.5 | $16M | 1.0M | 15.94 | |
Arvinas Ord (ARVN) | 3.0 | $14M | 330k | 41.28 | |
Iovance Biotherapeutics (IOVA) | 2.9 | $13M | 897k | 14.82 | |
Jasper Therapeutics Com New (JSPR) | 2.8 | $13M | 436k | 29.36 | |
Edgewise Therapeutics (EWTX) | 2.6 | $12M | 665k | 18.24 | |
Applied Therapeutics (APLT) | 2.6 | $12M | 1.8M | 6.80 | |
4d Molecular Therapeutics In (FDMT) | 2.4 | $11M | 344k | 31.86 | |
Codexis (CDXS) | 2.4 | $11M | 3.1M | 3.49 | |
Protara Therapeutics Com Stk (TARA) | 2.4 | $11M | 2.7M | 4.01 | |
Acelyrin (SLRN) | 2.3 | $11M | 1.6M | 6.75 | |
Crinetics Pharmaceuticals In (CRNX) | 2.1 | $9.8M | 210k | 46.81 | |
Eton Pharmaceuticals (ETON) | 2.0 | $9.2M | 2.4M | 3.75 | |
Trevi Therapeutics (TRVI) | 2.0 | $9.1M | 2.6M | 3.45 | |
Lyell Immunopharma (LYEL) | 1.6 | $7.5M | 3.4M | 2.23 | |
Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.6 | $7.5M | 315k | 23.65 | |
Ventyx Biosciences (VTYX) | 1.5 | $7.1M | 1.3M | 5.50 | |
Intellia Therapeutics (NTLA) | 1.5 | $7.0M | 255k | 27.51 | |
Compass Therapeutics (CMPX) | 1.4 | $6.3M | 3.2M | 1.98 | |
Xoma Corp Del Com New (XOMA) | 1.3 | $6.0M | 250k | 24.05 | |
Liquidia Corporation Com New (LQDA) | 1.3 | $5.8M | 395k | 14.75 | |
Vaxcyte (PCVX) | 1.3 | $5.8M | 85k | 68.31 | |
Nyxoah S A SHS (NYXH) | 0.9 | $4.3M | 320k | 13.49 | |
Savara (SVRA) | 0.9 | $4.3M | 855k | 4.98 | |
Syros Pharmaceuticals Com New (SYRS) | 0.9 | $4.2M | 788k | 5.35 | |
Urogen Pharma (URGN) | 0.9 | $4.1M | 270k | 15.00 | |
Nurix Therapeutics 67080M103 (NRIX) | 0.9 | $3.9M | 267k | 14.70 | |
Revance Therapeutics (RVNC) | 0.8 | $3.9M | 785k | 4.92 | |
Relmada Therapeutics (RLMD) | 0.8 | $3.5M | 759k | 4.65 | |
Protagonist Therapeutics (PTGX) | 0.7 | $3.3M | 113k | 28.93 | |
Gossamer Bio Note 5.000% 6/0 (Principal) | 0.7 | $3.2M | 8.0M | 0.40 | |
Zentalis Pharmaceuticals (ZNTL) | 0.7 | $3.2M | 200k | 15.76 | |
Allakos (ALLK) | 0.7 | $3.1M | 2.4M | 1.26 | |
Gossamer Bio (GOSS) | 0.6 | $2.9M | 2.4M | 1.18 | |
Ibio Com New (IBIO) | 0.6 | $2.8M | 680k | 4.06 | |
Verastem Com New (VSTM) | 0.5 | $2.5M | 211k | 11.80 | |
Aligos Therapeutics (ALGS) | 0.3 | $1.6M | 1.6M | 0.98 | |
Context Therapeutics (CNTX) | 0.3 | $1.5M | 1.1M | 1.38 | |
Precigen (PGEN) | 0.3 | $1.4M | 948k | 1.45 | |
Larimar Therapeutics (LRMR) | 0.3 | $1.3M | 174k | 7.59 | |
Fulcrum Therapeutics (FULC) | 0.3 | $1.2M | 130k | 9.44 | |
Morphosys Sponsored Ads (MOR) | 0.3 | $1.2M | 65k | 18.14 | |
Glaukos (GKOS) | 0.2 | $809k | 8.6k | 94.29 | |
Pmv Pharmaceuticals (PMVP) | 0.2 | $802k | 472k | 1.70 | |
Biodesix (BDSX) | 0.2 | $765k | 535k | 1.43 | |
Regulus Therapeutics (RGLS) | 0.1 | $491k | 170k | 2.88 | |
Design Therapeutics (DSGN) | 0.1 | $456k | 113k | 4.03 | |
Repare Therapeutics Ord (RPTX) | 0.1 | $318k | 68k | 4.71 |